A Deep Learning Framework with an Intermediate Layer Using the Swarm Intelligence Optimizer for Diagnosing Oral Squamous Cell Carcinoma

One of the most prevalent cancers is oral squamous cell carcinoma, and preventing mortality from this disease primarily depends on early detection. Clinicians will greatly benefit from automated diagnostic techniques that analyze a patient's histopathology images to identify abnormal oral lesions. A deep learning framework was designed with an intermediate layer between feature extraction layers and classification layers for classifying the histopathological images into two categories, namely, normal and oral squamous cell carcinoma. The intermediate layer is constructed using the proposed swarm intelligence technique called the Modified Gorilla Troops Optimizer. While there are many optimization algorithms used in the literature for feature selection, weight updating, and optimal parameter identification in deep learning models, this work focuses on using optimization algorithms as an intermediate layer to convert extracted features into features that are better suited for classification. Three datasets comprising 2784 normal and 3632 oral squamous cell carcinoma subjects are considered in this work. Three popular CNN architectures, namely, InceptionV2, MobileNetV3, and EfficientNetB3, are investigated as feature extraction layers. Two fully connected Neural Network layers, batch normalization, and dropout are used as classification layers. With the best accuracy of 0.89 among the examined feature extraction models, MobileNetV3 exhibits good performance. This accuracy is increased to 0.95 when the suggested Modified Gorilla Troops Optimizer is used as an intermediary layer.

Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer

Epithelial ovarian cancer (EOC) remains a significant cause of mortality among gynecologic cancers, with the majority of cases being diagnosed at an advanced stage. Before targeted therapies were available, EOC treatment relied largely on debulking surgery and platinum-based chemotherapy. Vascular endothelial growth factors have been identified as inducing tumor angiogenesis. According to several clinical trials, anti-vascular endothelial growth factor-targeted therapy with bevacizumab was effective in all phases of EOC treatment. However, there are currently no biomarkers accessible for regular therapeutic use despite the importance of patient selection. Microsatellite instability (MSI), caused by a deficiency of the DNA mismatch repair system, is a molecular abnormality observed in EOC associated with Lynch syndrome. Recent evidence suggests that angiogenesis and MSI are interconnected. Developing predictive biomarkers, which enable the selection of patients who might benefit from bevacizumab-targeted therapy or immunotherapy, is critical for realizing personalized precision medicine. In this study, we developed 2 improved deep learning methods that eliminate the need for laborious detailed image-wise annotations by pathologists and compared them with 3 state-of-the-art methods to not only predict the efficacy of bevacizumab in patients with EOC using mismatch repair protein immunostained tissue microarrays but also predict MSI status directly from histopathologic images. In prediction of therapeutic outcomes, the 2 proposed methods achieved excellent performance by obtaining the highest mean sensitivity and specificity score using MSH2 or MSH6 markers and outperformed 3 state-of-the-art deep learning methods. Moreover, both statistical analysis results, using Cox proportional hazards model analysis and Kaplan-Meier progression-free survival analysis, confirm that the 2 proposed methods successfully differentiate patients with positive therapeutic effects and lower cancer recurrence rates from patients experiencing disease progression after treatment (P < .01). In prediction of MSI status directly from histopathology images, our proposed method also achieved a decent performance in terms of mean sensitivity and specificity score even for imbalanced data sets for both internal validation using tissue microarrays from the local hospital and external validation using whole section slides from The Cancer Genome Atlas archive.